What rescheduling cannabis to Schedule III could mean for edibles and consumer safety

cannabis gummies

The debate over the classification of cannabis has been ongoing for decades, with opinions divided on its medicinal and recreational uses. As the conversation around cannabis legalization continues to evolve, there’s an important (but often overlooked) aspect of this discussion: the impact on consumer safety in the edibles market by rescheduling cannabis to Schedule III.

However, it’s first crucial to understand the current classification. Currently, cannabis is listed as a Schedule I substance – alongside heroin and LSD – indicating that it is deemed to have a high potential for abuse and no accepted medical use. Last year, the Biden Administration asked the Department of Health and Human Services (HHS) to reconsider the current classification of cannabis as a Schedule I drug. Rescheduling cannabis to Schedule III would recognize its medicinal benefits while allowing consumers to access edibles and ensuring a more consistent supply with fair prices.

RELATED: Eight major impacts of marijuana rescheduling on publicly traded cannabis companies

What rescheduling means for the edibles market

One of the most significant changes would be the regulation of edibles. In states where cannabis is legal, edibles have become increasingly popular due to their convenience and on-demand discretion. A move to Schedule III would bring these products under greater scrutiny, ensuring that they meet rigorous safety and quality standards – like other drugs, foods, and beverages regulated by federal agencies. This would include accurate labeling of cannabinoids and other, sometimes hidden ingredients to prevent unintentional overconsumption and put the onus on manufacturers to increase transparency, which are both common concerns with edibles.

Currently, there are state-by-state regulations for the amount of THC in each edible and other testing requirements that manufacturers must meet before their products hit dispensary shelves. With increased oversight by an agency like the FDA after rescheduling, manufacturers may also have a set of consumer safety standards they must meet with the other ingredients in emulsions and nanotechnology used for greater bioavailability and faster onset in edibles – something that is not required today.   

Schedule III classification would also promote research into the effects of edibles on consumer health. The current lack of research into edibles means that consumers often lack clear information about their effects and potential risks. A shift to Schedule III could facilitate studies to provide consumers with more information about the safety and proper use of these products.

Final thought

Rescheduling cannabis has the potential to improve consumer safety in the edibles market as long as new guidelines are proposed and enforced. By acknowledging its medicinal benefits while imposing stricter regulations, we can ensure that consumers have access to safe and accurately labeled products. This shift would not only benefit consumers but also contribute to a more informed and responsible approach to cannabis use.

Consumer education and safety should be at the forefront of this discussion. The shift to Schedule III has the potential to usher in an era where edibles are crafted and labeled with utmost care and responsibility. It could be the linchpin for responsible consumption, casting consumers as the heroes of their own adventures, armed with the knowledge they need to make well-informed choices. It’s time to revolutionize safety and knowledge. 

This article was submitted by a guest contributor to GreenState. The statements within do not necessarily reflect the opinions of GreenState, Hearst, or its subsidiaries. The author is solely responsible for the content.

Josh Rubin Josh Rubin is the CEO and co-founder of Day Three Labs. Josh began his career in cannabis in 2017 as a consultant, analyzing trends in the cannabis market, including fluctuations in wholesale price-points, as well as patterns and anomalies in publicly traded cannabis companies. In addition, he managed product development projects, working with Israeli scientists to provide innovative solutions to U.S. cannabis brands.